Y-mAbs Therapeutics rises on approval of cancer drug in Brazil

Y-mAbs Therapeutics

23/05/2023 18:43

** Shares of Y-mAbs Therapeutics Inc  YMAB.O  rise 6% to
$10.17
    ** Co says Brazilian Health Regulatory Agency ANVISA granted
marketing authorization for its DANYELZA 40mg/10mL injection
    ** Adds that DANYELZA will be marketed in Brazil by co's
partner Adium Pharma S.A.
    ** DANYELZA is an antibody that helps treat High-Risk
Neuroblastoma or nerve tissue cancer
    ** "We continue to focus on expansion of DANYELZA in other
jurisdictions, working to provide access to children living with
refractory or relapsed neuroblastoma," says interim CEO Thomas
Gad
    ** Including session's gains, stock has risen 109.73% YTD

 (Reporting by Sruthi Narasimha Chari in Bengaluru)
 ((Sruthinarasimha.chari@thomsonreuters.com))